Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Search Study Connect
BMS Recruiting Study icon

Recruiting

Trial ID IM011-054  |   NCT04908202

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Summary

  • Phase 3
  • Male and Female Gender icon
  • 18+
    Age Range
  • 120
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
  • Diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at screening.
    1. Meets the Classification Criteria for Psoriatic Arthritis at Screening.
      1. Active plaque psoriatic skin lesion(s) or documented medical history of plaque psoriasis (PsO) at screening.
        1. Active arthritis as shown by ≥ 3 swollen joints and ≥ 3 tender joints at Screening and day 1.
          1. Participant has high sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening.
            1. ≥ 1 PsA-related hand and/or foot joint erosion on X-ray during Screening Period that is confirmed by central reading.
              1. Must have completed the week 52 treatment for the optional open-label long-term extension period.

                Exclusion Criteria

                Exclusion Criteria Icon
                • Nonplaque psoriasis at screening or day 1.
                  1. Other autoimmune condition such as systemic lupus erythematous, mixed connective tissue disease, multiple sclerosis, or vasculitis.
                    1. History of or current inflammatory joint disease other than PsA (e.g., gout, reactive arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease).
                      1. Active fibromyalgia.
                        1. Received an approved or investigational biologic therapy for the treatment of PsA or PsO.
                          Additional Information *
                          • Other protocol-defined Inclusion/Exclusion criteria apply.

                            Treatment Options

                            Study Arms

                            ASSIGNED INTERVENTION

                            Study Arms

                            Experimental: Deucravacitinib

                            ASSIGNED INTERVENTION
                            • Drug: Deucravacitinib

                            Study Arms

                            Placebo Comparator: Placebo

                            ASSIGNED INTERVENTION
                            • Other: Placebo
                            Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility
                            Check Your Eligibility
                            Answer some questions about Your health to see if you may match to this trial
                            Match to a Trial
                            If you are a match, click on the study to see the list of study site locations
                            Select a Study Site Location
                            Select a study site location that is convenient for you
                            Register
                            Provide your contact details for the study site to connect with you.

                            We strongly recommend you contact BMS to report Side Effects (Adverse Events)
                            Side Effects (Adverse Events) and other reportable events are defined here
                            Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

                            Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

                            Have questions? Live support is available 24/7 -
                            Call 855-907-3286 or email clinical.trials@bms.com